P1027: Assessment of body fat composition in patients with inflammatory bowel diseases by bioelectrical impendance analysis: a single-centre studyECCO'25Year: 2025
Authors: Vukovic, J.(1);Sundov, Z.(2)*;Sustic, I.(2);Ivana, J.(2);Ana, K.(3);
(1)CHC Split, Gastroenterology, Split, Croatia;(2)Clinical Hospital Split, Gastroenterology, Split, Croatia;(3)Health Center of Split-Dalmatia County, Family Medicine, Split, Croatia; J Vukovic Sustic I Jukic I Krizman A
1.Jabłońska B, Mrowiec S. Nutritional Status and Its Detection in Patients with Inflammatory Bowel Diseases. Nutrients. 2023;15(8).
2. Bischoff SC, Escher J, et al. ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clinical nutrition (Edinburgh, Scotland). 2020;39(3):632-53.
P1028: Personalised co-culture model of intestinal organoids and immune cells for evaluating biological therapy response in ulcerative colitis patients.ECCO'25Year: 2025
Authors: Tilinde, D.(1)*;Inciuraite, R.(1);Kulokiene, U.(1);Kiudelis, V.(2);Jonaitis, L.V.(2);Kupcinskas, J.(2);Skieceviciene, J.(1);
(1)Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania;(2)Lithuanian University of Health Sciences, Institute for Digestive Research and Department of Gastroenterology, Kaunas, Lithuania;
1Le Berre, C., et al. (2023). Ulcerative colitis. The Lancet. 402(10401):571-584. doi:10.1016/S0140-6736(23)00966-2
2Singh, S., et al. (2020). AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 158(5):1465-1496.e17. doi:10.1053/j.gastro.2020.01.007.
P1029: Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre StudyECCO'25Year: 2025
Authors: Gilmore, R.(1)*;Fernandes, R.(1);Chin, S.(2);Con, D.(2);De Cruz, P.(2);Demase, K.(3);Sparrow, M.(3);Thin, L.(4);Baker, J.(5);Venugopal, K.(5);Lucas, S.(6);Garg, M.(6);Loebenstein, M.(7);Nguyen, A.(7);Moore, G.(7);Tandon, B.(8);Bryant, R.(8);MacFarlane, K.(9);Lynch, K.(9);Abdul, S.(9);Subhaharan, D.(10);Mohsen, W.(10);Haig, A.(11);Day, M.(11);White, L.(11);Begun, J.(1);An, Y.K.(1);
(1)Mater Hospital Brisbane, Gastroenterology, Brisbane, Australia;(2)Austin Health, Gastroenterology, Melbourne, Australia;(3)Alfred Health, Gastroenterology, Melbourne, Australia;(4)Fiona Stanley Hospital, Gastroenterology, Perth, Australia;(5)Royal Perth Hospital, Gastroenterology, Perth, Australia;(6)Northern Health, Gastroenterology, Melbourne, Australia;(7)Monash Health, Gastroenterology, Melbourne, Australia;(8)The Queen Elizabeth Hospital, Gastroenterology, Adelaide, Australia;(9)Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia;(10)Gold Coast University Hospital, Gastroenterology, Gold Coast, Australia;(11)Sunshine Coast University Hospital, Gastroenterology, Sunshine Coast, Australia;
P1030: Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: Subgroup analysis of the Phase 3 GRAVITI studyECCO'25Year: 2025
Authors: Liu, W.(1);Guo, H.(2);Kim, T.O.(3);Takeuchi, K.(4);Hisamatsu, T.(5);Fable, J.(6);Olurinde, M.(6);Wahking, B.(7);Zhuo, J.(8);Cao, Q.(9)*;
(1)The Second People’s Hospital of Changzhou- the Third Affiliated Hospital of Nanjing Medical University- Changzhou- 213003- China, na, Changzhou, China;(2)Chongqing General Hospital- Chongqing University- Chongqing- 400014- China, na, Chongqing, China;(3)Department of Internal Medicine- Haeundae Paik Hospital- Inje University College of Medicine- Busan- Korea, na, Busan, Korea- Republic Of;(4)Director of Gastroenterology- Manager of IBD Centre- Tsujinaka Hospital Kashiwanoha- 146-6 Kashiwanoha Campus- 178-2 Wakashiba- Kashiwa city- Chiba 277-0871- Japan, na, Chiba, Japan;(5)Department of Gastroenterology and Hepatology- Kyorin University School of Medicine- Tokyo- Japan, na, Tokyo, Japan;(6)Janssen Research & Development- LLC- Spring House- PA- USA, na, Spring House, United States;(7)Janssen Asia Pacific- Singapore, na, Singapore, Singapore;(8)Janssen China R&D- Shanghai- China, na, Shanghai, China;(9)Sir Run Run Shaw Hospital Affiliated with School of Medicine- Zhejiang University- Hangzhou- China, na, Hangzhou, China;
1. Panaccione R, Danese S, Feagan BG, et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn’s disease: results of the GALAXI 2 & 3 phase 3 studies. Gastroenterology. 2024;166(5 Suppl):1057b-1057b2
2. Panaccione R, Hart A, Steinwurz F, Danese S, Hisamatsu T, Cao Q, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: results through week 48 from the phase 3 GRAVITI study. Oral presentation 72. In: American College of Gastroenterology 2024 Annual Scientific Meeting; October 25-30, 2024; Philadelphia, PA, USA.
P1031: Effectiveness and safety of oral vancomycin in the treatment of non-primary sclerosing cholangitis paediatric Inflammatory Bowel Disease (non-PSC PIBD) patients: a real-world single-center cohort studyECCO'25Year: 2025
Authors: Gianolio, L.(1)*;Ancona, S.(1);Armstrong, K.(1);Rabone, R.(1);Merrick, V.(1);Henderson, P.(1,2);Wilson, D.C.(1,2);Russell, R.K.(1,2);
(1)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(2)University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom;
1. Ricciuto A, Liu K, El-Matary W, et al. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther. 2024;59(10):1236-1247. doi:10.1111/apt.17936.
2. Turner D, Bishai J, Reshef L, et al. Antibiotic cocktail for pediatric acute severe colitis and the microbiome: The PRASCO randomized controlled trial. Inflamm Bowel Dis. 2020;26(11):1733-1742. doi:10.1093/ibd/izz298.
3. Lev-Tzion R, Ledder O, Shteyer E, Tan MLN, Uhlig HH, Turner D. Oral Vancomycin and Gentamicin for Treatment of Very Early Onset Inflammatory Bowel Disease. Digestion. 2017;95(4):310-313. doi:10.1159/000475660
P1033: The decrease of 6-TGN concentrations during pregnancy is not associated with an increase in fecal calprotectin in female patients with IBD on thiopurine-treatmentECCO'25Year: 2025
Authors: Bouwknegt, D.G.(1)*;Mian, P.(2);Groen, F.(2);van den Berg-Zuiddam, D.(3);van der Meulen, A.E.(3);Crouwel, F.(4);de Boer, K.H.N.(4);Deben, D.(5);Wong, D.R.(6);Derijks, L.J.J.(7);Dijkstra, G.(1);Bourgonje, A.R.(1,8);van der Woude, C.J.(9);Visschedijk, M.C.(1);
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Clinical Pharmacy and Pharmacology, Groningen, The Netherlands;(3)Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands;(4)Amsterdam University Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Zuyderland Medical Center, Clinical Pharmacy and Pharmacology, Heerlen, The Netherlands;(6)Zuyderland Medical Center, Clinical Pharmacy- Pharmacology- and Toxicology, Sittard-Geleen/Heerlen, The Netherlands;(7)Máxima Medical Center, Clinical Pharmacy and Pharmacology, Veldhoven, The Netherlands;(8)Icahn School of Medicine at Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(9)Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands; Dutch Initiative on Crohn and Colitis (ICC)
References
1. Flanagan E, Wright EK, Hardikar W, et al. Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Aliment Pharmacol Ther. 2021;53:810-820.
2. Jharap B, De Boer NKH, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63(3):451-457. doi:10.1136/gutjnl-2012-303615
P1034: Prognostic value of short-term endo-histological outcomes in moderate-to severe ulcerative colitis patients on tofacitinib treatment – prospective cohort studyECCO'25Year: 2025
Authors: Resál, T.(1,2)*;Bacsur, P.(3);Farkas, B.(4);Ivány, E.(4);Bálint, A.(4);Bősze, Z.(4);Fábián, A.(4);Bor, R.(4);Tóth, T.(4);Szepes, Z.(4);Farkas, K.(4,5);Molnár, T.(4);
(1)Central Hospital of Northern Pest - Military Hospital, Department of Gastroenterology-, Budapest, Hungary;(2)HCEMM-USZ, Translational Colorectal Research Group, Szeged, Hungary;(3)University of Szeged, Department of Gastroenterology, Szeged, Hungary;(4)University of Szeged, Department of Gastroenterology-, Szeged, Hungary;(5)HCEMM, Translational Colorectal Research Group, Szeged, Hungary;
P1035: The Effects of an Intermittent Reduced Calorie Diet on Crohn’s DiseaseECCO'25Year: 2025
Authors: Kulkarni, C.(1);Fardeen, T.(1);Gubatan, J.(1);Jarr, K.(2);Dickson, E.(1);Jang, H.(1);Temby, M.(1);Patel, A.(1);Singh, G.(1);Ye, J.(1);Keyashian, K.(1);Streett, S.(1);Ho, E.(1);Barber, G.(1);Singh, S.(1);Limsui, D.(1);Anaizi, N.(3);Becker, L.(1);Spencer, S.(1);Mehrish, D.(1);Perelman, D.(1);Habtezion, A.(1);Sonnenburg, J.(4);Gardner, C.(5);Sinha, S.(1)*;
(1)Stanford University School of Medicine, Gastroenterology, Stanford, United States;(2)Heidelberg University Hospital, Internal Medicine & Gastroenterology, Heidelberg, Germany;(3)Stanford Health Care, Gastroenterology, Stanford, United States;(4)Stanford University School of Medicine, Microbiology and Immunology, Stanford, United States;(5)Stanford University School of Medicine, Stanford Prevention Research Center, Stanford, United States;
1. Wei M, Brandhorst S, Shelehchi M, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017;9(377).
2. Gubatan J, Kulkarni CV, Talamantes SM, Temby M, Fardeen T, Sinha SR. Dietary Exposures and Interventions in Inflammatory Bowel Disease: Current Evidence and Emerging Concepts. Nutrients. 2023;15(3):579.
P1036: The PODIUM Study: A three-arm comparison of target therapies after anti-TNFα in ulcerative colitis – an interim analysisECCO'25Year: 2025
Authors: Privitera, G.(1)*;Bezzio, C.(2);Savarino, E.(3);Pugliese, D.(4);Noviello, D.(5);Rodriguez-Lago, I.(6);Barreiro de Acosta, M.(7);Onali, S.(8);Fantini, M.(8);Kopylov, U.(9);Karmiris, K.(10);Yanai, H.(11);Gutierrez-Casbas, A.(12);Pastorelli, L.(5);Chaparro, M.(13);Zabana, Y.(14);Armuzzi, A.(2);
(1)Humanitas Research Hospital, Dipartimento di Medicina Interna, Milano, Italy;(2)Humanitas Research Hospital, IBD Unit, Milan, Italy;(3)Università di Padova, IBD Unit, Padova, Italy;(4)Policlinico Universitario Gemelli IRCCS, IBD Unit, Rome, Italy;(5)Università degli Studi di Milano, IBD Unit, Milan, Italy;(6)Hospital Universitario de Galdakao, IBD Unit, Galdakao, Spain;(7)University Hospital of Santiago, IBD Unit, Santiago de Compostela, Spain;(8)Università di Cagliari, IBD Unit, Cagliari, Italy;(9)Sheba Medical Centre, IBD Unit, Tel Aviv, Israel;(10)Venizeleio General Hospital, IBD Unit, Heraklion, Greece;(11)RABIN Medical Center, IBD Unit, Tel Aviv, Israel;(12)Hospital General Universitario Alicante, IBD Unit, Alicante, Spain;(13)Hospital Universitario de La Princesa, IBD Unit, Madrid, Spain;(14)Hospital Universitario de La Princesa, IBD Unit, Terrassa, Spain;
P1037: Prevalence and factors associated with obesity in patients with IBD treated with infliximab and vedolizumab across the United Kingdom (UK)ECCO'25Year: 2025
Authors: Roberts, C.(1)*;Hodges, P.(1);Badrulhisham, F.(1);Smith, R.(1);Vida, C.(1);Bewshea, C.(2);Kennedy, N.(1);Goodhand, J.(1);Ahmad, T.(1);
(1)Royal Devon University Healthcare NHS Trust, Gastroenterology, Exeter, United Kingdom;(2)Exeter IBD Research Group, Gastroenterology, Exeter, United Kingdom;
1 . Kennedy NA, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27. PMID: 30824404 2. Kennedy NA, Goodhand JR, Bewshea C Contributors to the CLARITY IBD study, et alAnti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 2021;70:865-875 3. Access to Healthy Assets & Hazards (AHAH) Version 3, Consumer Data Research Centre, Accessed 18th November 2024
P1039: An Evaluation of Anti-IL23 Therapy in Primary Sclerosing Cholangitis Associated Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Al-Shakhshir, S.(1)*;Morris, S.(2);Kaur, S.(3);Culver, E.(4);Elzubeir, A.(5);Rushbrook, S.(5);Nayagam, J.S.(6);Joshi, D.(6);Hernandez-Evole, H.(7);Schregel, I.(8);Schramm, C.(9);Rodriguez, S.(7);Leibovitzh, H.(10);Shibolet, O.(11);Cristoferi, L.(12);Vigano, C.(13);Carbone, M.(12);Invernizzi, P.(14);Trivedi, P.(15);
(1)University of Birmingham, Institute for Biomedical Research- Centre for Liver and Gastrointestinal Diseases, Birmingham, United Kingdom;(2)University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom;(3)Oxford University Hospitals NHS Foundation Trust, Department of Gastroenterology and Hepatology, Oxford, United Kingdom;(4)Oxford University Hospitals NHS Foundation Trust, Department of Hepatology, Oxford, United Kingdom;(5)Norfolk and Norwich University Hospitals NHS Trust, Department of Hepatology, Norwich, United Kingdom;(6)King’s College Hopsital NHS Foundation Trust, Hepatology, London, United Kingdom;(7)Hospital Clínico de Barcelona, Hepatology, Barcelona, Spain;(8)University Medical Centre Hamburg-Eppendorf, Department of Gastroenterology and Hepatology, Hamburg, Germany;(9)University Medical Centre Hamburg-Eppendorf, Hepatology, Hamburg, Germany;(10)Tel Aviv Sourasky Medical Center, Gastroenterology and Hepatology, Tel Aviv, Israel;(11)Tel Aviv Sourasky Medical Center, Hepatology, Tel Aviv, Israel;(12)University of Milano-Bicocca, Hepatology, Milan, Italy;(13)Fondazione IRCCS San Gerardo dei Tintori Monza-, Hepatology, Monza, Italy;(14)University of Milano-Bicocca-, Hepatology, Milan, Italy;(15)University of Birmingham, Institute for Biomedical Research- Centre of Liver and Gastrointestinal Diseases, Birmingham, United Kingdom;
P1040: Steroid use and dependency in South Indian Inflammatory Bowel Disease patients- A multi-center clinical auditECCO'25Year: 2025
Authors: Mandapati, C.S.P.(1)*;Kuriakose Kuzhiyanjal, A.(2);Musunuri , B.(1);Desai , G.(3);Anasosalu , S.(4);Tantry, B.V.(5);A k Satheesh, R.(4);Hajare, S.(3);Shetty, S.(1);Limdi, J.K.(2);
(1)Kasturba medical college, Medical Gastroenterology, Manipal, India;(2)Northern Care Alliance NHS Foundation Trust, Division of Gastroenterology- Section of IBD, Manchester, United Kingdom;(3)Jawaharlal Nehru Medical College, Medical Gastroenterology, Belgaum, India;(4)Narayana Multispecialty Hospital, Medical Gastroenterology, Mysore, India;(5)Kasturba Medical College, Medical Gastroenterology, Mangaluru, India;
1. Selinger CP, Parkes GC, Bassi A, et al. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017
2. Raine T, Bonovas S, Burisch J et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022
P1041: Efficacy and Safety of Adalimumab Biosimilar Dose Escalation Treatment in biologic naïve Patients With fistulas Crohn's Disease: A Prospective, Single-Arm Clinical PracticeECCO'25Year: 2025
Authors: Cheng, Y.(1)*;Wang, H.(2);Yu, Q.(2);Zhu, L.(2);
(1)Department of Gastroenterology- Union Hospital- Tongji Medical College- Huazhong University of Science and Technology- Wuhan- China., Department of Gastroenterology- Union Hospital- Tongji Medical College- Huazhong University of Science and Technology- Wuhan- China., Wuhan, China;(2)Department of Gastroenterology- Union Hospital- Tongji Medical College- Huazhong University of Science and Technology- Wuhan- China, Department of Gastroenterology- Union Hospital- Tongji Medical College- Huazhong University of Science and Technology- Wuhan- China, Wuhan, China;
P1042: Effectiveness and safety of vedolizumab in real-world studies in Chinese patients with inflammatory bowel disease: a systematic review and meta-analysisECCO'25Year: 2025
Authors: Gu, Y.(1)*;Zhang, X.(2);Gu, L.(2);Zou, D.(1);
(1)Ruijin Hospital- Shanghai Jiao Tong University School of Medicine, Department of Gastroenterology, Shanghai, China;(2)Takeda China International Trading Co.- Ltd., Medical affairs, Shanghai, China;
P1043: Efficacy of intravenous ustekinumab maintenance treatment in patients with Inflammatory Bowel Disease with partial response or loss of response to subcutaneous ustekinumab: A single centre, observational, retrospective study.ECCO'25Year: 2025
Authors: Jarrín Pesantes, V.C.(1)*;Moralejo Lozano, Ó.(1);Abanades Tercero, M.(1);Ruano Pérez, L.(1);Salmoral Luque, R.(1);Muñoz Rosas, C.(1);Gómez Rodríguez, R.Á.(1);
(1)Hospital Universitario de Toledo, Gastroenterology and Hepatology Department, Toledo, Spain;
- Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773.
- Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381(13):1201-1214. doi:10.1056/NEJMoa1900750.
- Suárez Ferrer C, Arroyo Argüelles J, Rueda García JL, et al. Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease. J Clin Med. 2024;13(3):669. Published 2024 Jan 24. doi:10.3390/jcm13030669.
- López-Sáez B, Brunet-Mas E, Melcarne L, et al. P895 Analysis of the efficacy of intravenous ustekinumab maintenance treatment in patients with refractory Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(Suppl 1):i1643. doi:10.1093/ecco-jcc/jjad212.1025.
P1044: Effectiveness of adjunctive use of antibiotics in Acute Severe Ulcerative ColitisECCO'25Year: 2025
Authors: Hyun, H.K.(1)*;Park, J.(2);Park, S.J.(2);Park, J.J.(2);Kim, T.I.(2);Cheon, J.H.(2);
(1)Yonsei University College of Medicine Yongin Severance Hospital, Gastroenterology, Yongin, Korea- Republic Of;(2)Yonsei University College of Medicine- Severance Hospital, Internal Medicine, Seoul, Korea- Republic Of;
1. Barnes EL, Agrawal M, Syal G, et al. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Gastroenterology 2024;166:59-85.
2. Abraham B, Quigley EMM. Antibiotics and probiotics in inflammatory bowel disease: when to use them? Frontline Gastroenterol 2020;11:62-9.
3. Imhann F, Vich Vila A, Bonder MJ, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 2018;67:108-19.
4. Singh S, Allegretti JR, Siddique SM, et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1465-96.e17.5.
5. Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol 2018;16:343-56.e3.
6. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-7.
7. Dahiya D, Nigam PS. Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. Int J Mol Sci 2023;24.
8. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
9. Rivière P, Li Wai Suen C, Chaparro M, et al. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol 2024;9:251-62.
10. Ramirez J, Guarner F, Bustos Fernandez L, et al. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol 2020;10:572912.
P1045: Treat-smart study: Leveraging individual inflammatory markers for personalized therapy in patients with IBDECCO'25Year: 2025
Authors: Medhat, M.(1)*;Ramadan, Y.N.(2);Hashem, M.(1);Doaa, A.(1);Nariman, Z.(1);Hetta, H.F.(3);
(1)Assiut University, Tropical Medicine and Gastroenterology Department- Assiut University Hospital, Assiut, Egypt;(2)Assiut University, Department of Microbiology and Immunology- Faculty of Pharmacy, Assiut, Egypt;(3)Assiut University, 1- Division of microbiology- immunology and biotechnology- Department of Natural Products and Alternative Medicine- Faculty of Pharmacy- University of Tabuk- Tabuk- 2- Department of Medical Microbiology and Immunology- Faculty of Medicine, Assiut, Egypt; "Assiut Tropical IBD Study Group" (ATISG)
P1046: Risk Factors for Complications After Crohn's Disease Surgery : A tertiary monocentric studyECCO'25Year: 2025
Authors: Aouroud, H.(1)*;Aouroud, M.(1);Lairani, F.E.(1);Nacir, O.(1);Ait Errami, A.(1);Oubaha, S.(1);Samlani, Z.(1);Krati, K.(1);
(1)Mohammed VI university Hospital, Gastro-enterology, Marrakech, Morocco;
P1047: Moderate and severe iron deficiency anaemia responds better to oral iron therapy than mild iron deficiency anaemia in Crohn's Disease patients: a prospective study in a resource-limited settingECCO'25Year: 2025
Authors: Chinthala, H.(1)*;Dutta, A.K.(1);Polavarapu, J.(1);Joseph, A.J.(1);Simon, E.G.(1);Chowdhury, S.D.(1);Kurien, R.T.(1);John, A.(1);Jaleel, R.(1);Thomas, A.(1);Abraham, D.(2);Benny, B.(2);
(1)Christian Medical College Vellore, Gastroenterology, Ranipet, India;(2)Christian Medical College Vellore, Microbiology, Vellore, India;
1. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3): 211-222.doi:10.1093/ecco-jcc/jjv010
